Tech Company Financing Transactions
Agilis Biotherapeutics Funding Round
Private investors participated in a $8 million capital raise for Agilis Biotherapeutics. The round was announced on 1/3/2014.
Transaction Overview
Company Name
Announced On
1/3/2014
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the financing will be used for Agilis' initial focus on developing a treatment for Friedreich's ataxia FRDA) in collaboration with Intrexon Corporation (XON), a leader in the field of synthetic biology.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
245 First St. Kendall Square 1800
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Agilis Biotherapeutics is focused on designing and engineering DNA-based therapeutics for life-threatening or fatal rare diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Pykett
Chief Medical Officer
Kirsten Gruis
VP - Finance
Kevin O'Brien
VP - Operations
Anne Conway
VP - Operations
Jodi Cook
Browse more venture capital transactions:
Prev: 1/2/2014: 1World Online venture capital transaction
Next: 1/3/2014: Tute Genomics venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs